Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Hannah Linden"'
Autor:
Kevin J. Donohoe, Brett J. Carroll, David K. V. Chung, Elizabeth H. Dibble, Emilia Diego, Francesco Giammarile, Frederick D. Grant, Stephen Y. Lai, Hannah Linden, Megan E. Miller, Neeta Pandit-Taskar, Nicholas E. Tawa, Sergi Vidal-Sicart
Publikováno v:
Journal of Nuclear Medicine. 64:525-528
Autor:
Poorni Manohar, Hannah Linden, Veena Shankaran, Catherine Fedorenko, Jenna Voutsinas, Qin Sun, Vicky Wu
Publikováno v:
Cancer Research. 83:P4-07
Background: Evidence-based recommendations for the management of metastatic breast cancer (MBC) endorse confirmation of recurrence with biopsy and reassessment of biomarker status. National guidelines support numerous treatment options and do not cap
Autor:
Alejandra Perez, Hannah Linden, Nathalie Johnson, Sami Diab, Chirag Jani, Chelsea D. Gawryletz, Richard Fine, Laura Lawson, Megan Baker, Victoria Poillucci, Lisa E. Blumencranz, William Audeh
Publikováno v:
Cancer Research. 83:OT2-05
FLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols BACKGROUND: Genomic signatures, such as the 70-gene MammaPrint, provide additional prognostic information for early-stage b
Publikováno v:
Breast Cancer Research and Treatment. 194:507-516
To compare the outcome of allogeneic stem cell transplantation for myeloid malignancies in breast cancer survivors to a contemporaneous control group.Medical records of all patients with a history of breast cancer who received allogeneic stem cell tr
Autor:
Clifford Hudis, Alison L. Hannah, Larry Norton, Sujata Patil, Weining Ma, Steven Sugarman, Mary E. Moynahan, Maura Dickler, Gabriella D'Andrea, Neal Rosen, Sarat Chandarlapaty, David Solit, Hannah Linden, Alison Stopeck, Shanu Modi
Purpose: HSP90 is a chaperone protein required for the stability of a variety of client proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 and inhibits its activity, thereby inducing the degradation of these clients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::004a46f7e16535013626a7738683baf6
https://doi.org/10.1158/1078-0432.c.6519137
https://doi.org/10.1158/1078-0432.c.6519137
Autor:
Clifford Hudis, Alison L. Hannah, Larry Norton, Sujata Patil, Weining Ma, Steven Sugarman, Mary E. Moynahan, Maura Dickler, Gabriella D'Andrea, Neal Rosen, Sarat Chandarlapaty, David Solit, Hannah Linden, Alison Stopeck, Shanu Modi
CCR Translation for This Article from HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56faa053d339adcfa9292c777d5efbc2
https://doi.org/10.1158/1078-0432.22442405
https://doi.org/10.1158/1078-0432.22442405
Autor:
Mario Campone, Sarat Chandarlapaty, Aditya Bardia, Patrick Neven, Katarina Petrakova, Peter Kabos, Valentina Boni, Sofia Braga, Marina Celanovic, Patrick Cohen, Alice Gosselin, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Hannah Linden
Publikováno v:
Cancer Research. 82:OT2-11
Background Endocrine therapy in combination with a targeted cyclin-dependent kinase (CDK) 4/6 inhibitor is the clinical standard for treatment of ER+/HER2- advanced breast cancer. Amcenestrant (SAR439859) is an optimized oral SERD with potent dual ac
Autor:
Adam Brufsky, Hannah Linden, Hope Rugo, Charles Vogel, Joyce A O'Shaughnessy, Robert H Getzenberg, K. Gary Barnette, Domingo Rodriguez, Mitchell S Steiner, Erica Mayer
Publikováno v:
Cancer Research. 82:OT2-17
Targeting the androgen receptor (AR) may be the next important endocrine therapy for women with advanced breast cancer. AR is the most abundantly expressed steroid receptor in breast cancer and has been demonstrated to be a tumor suppressor when acti
Autor:
Natasha Hunter, Lanell M. Peterson, David A. Mankoff, Mark Muzi, Delphine Chen, William R. Gwin, Shaveta Vinayak, Nancy E Davidson, Jennifer M. Specht, Hannah Linden
Publikováno v:
Cancer Research. 83:P2-03
Background: 18F-Fluorodeoxyglucose (FDG) has long been used for measuring tumor glycolytic activity in clinical PET imaging. The FDA recently approved 18F-Fluoroestradiol (FES) (Cerianna) as a PET imaging tracer for characterizing disease in patients
Autor:
Natasha Hunter, Lanell M. Peterson, Mark Muzi, Eric Q. Konnick, Jonathan Reichel, Paul Kinahan, Jennifer M. Specht, Rachel Yung, William R. Gwin, Hannah Linden, Christina Tran
Publikováno v:
Cancer Research. 83:P2-03
Background: 18F-FES is an FDA-approved estrogen analogue PET imaging tracer (Cerianna) which measures tumor estrogen receptor (ER) expression at multiple tumor sites simultaneously and predicts response to endocrine therapy. 18F-FDG is a commonly use